Abstract library

1762 results for ": neuroendocrine tumours".
#2224 Neuroendocrine Tumours in Tailgut Cysts: A Report of 3 Cases and Review of Literature
Introduction: Retrorectal neuroendocrine tumors (NETs) are rare low grade tumors and their presence in tailgut cyst is rarer.
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: Prasad Pande
Authors: Pande P, D G, Shah R, Palepu J
#1107 The Chicken Chorioallantoic Membrane Assay as a Preclinical Model for the Research of Rare Gastrointenstinal Neuroendocrine Tumours
Introduction: Preclinical trials of cancer therapeutics require both in vitro and in vivo evaluations. For neuroendocrine tumours (NET) studies are limited to cell lines, thus xenograft models are needed for screening and evaluation of anti-cancer drugs. The chick chorioallantoic membrane (CAM) assay is a well-established model system to investigate tumour growth, angiogenesis and metastasis.
Conference: 12th Annual ENETS Conference (2015)
Category: ...none of the below
Presenting Author: PhD Nassim Ghaffari Tabrizi-Wizsy
Authors: Passegger C, Kump P, Haybäck J, Lipp R, ...
#1576 Neuroendocrine Tumours: A Retrospective Analysis in a Single Irish Institution
Introduction: Neuroendocrine tumours(NETs)are heterogenous group of tumours.
Conference: 13th Annual ENETS conference (2016)
Category: ...none of the above
Presenting Author: DR Cha Len Lee
Keywords: neuroendocrine
#2163 Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Carcinomas: Case Series
Introduction: High-grade neuroendocrine carcinomas (NECs) possess inevitable tendencies to metastasise and hold poor prospects of survival. Patients with neuroendocrine tumours who progress after medical management can be treated with peptide receptor radionuclide therapy (PRRT), on the proviso that there is positive uptake on 68Ga-DOTATATE PET/CT imaging. Despite this, a proportion of patients who exhibit positive imaging respond poorly to therapy. Management of NECs is currently limited; evidence for treating NECs with PRRT is scarce.
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: Shamus Butt
Authors: Butt S, Evans J, Sharma R, ...
#2225 Long Term Survival after Transplant for Neuroendocrine Liver Metastases: A Case Report and Literature Review
Introduction: Liver transplantation (LT) is offered to selected patients of neuroendocrine tumours (NETs) with unresectable liver metastases (NELM).
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: Prasad Pande
Authors: Pande P, Desai G, Shah R, Palepu J, ...
#2250 Treatment Outcomes of Patients with Mixed Neuroendocrine Non-Neuroendocrine Neoplasms (MiNEN)
Introduction: Mixed neuroendocrine non-neuroendocrine neoplasms (MiNEN) have been newly defined in the WHO 2017 classification. They are rare tumors, commonly treated in analogy to their non-neuroendocrine (nNE) or neuroendocrine (NE) component without systematic data regarding the optimal therapeutic strategy.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Dr. med. Leonidas Apostolidis
#56 Somatostatinreceptor scintigraphy with Tc-99m-tektrotyd in patients with neuroendocrine tumors: correlation with immunohistochemistry
Introduction: Somatostatin receptor scintigraphy (STRS) with Tc-99m-tektrotyd has been used in the past few years for diagnosis and staging of neuroendocrine tumors (NETs). A number of clinicopathologic criteria proved to be useful predictors of malignant behavior of these tumors. Immunohistochemical markers for NETs include cell proliferation (Ki-67 index) and neuroendocrine markers such as chromogranin A (CgA) and synaptophysin.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Prof Margarida Rodrigues
#62 Genome-wide DNA methylation profiling of pancreatic neuroendocrine tumors identifies distinct methylation profiles and differentially methylated gene promoter regions associated with low, medium and high grade tumors
Introduction: Integration of genetics and epigenetics has emerged as a powerful approach to studying cellular differentiation (Mikkelsen et al, 2009) and tumorigenesis (Shen et al, 2007). The study of DNA methylation is of particular importance in cancer, as causal involvement has been demonstrated and it is the most stable of all epigenetic modifications, making it a desirable marker for both early detection and treatment of tumors. Hypermethylation of CpG sites in gene promoter regions leads to decreased gene expression; if such a gene is a tumor suppressor, this leads to carcinogenesis. To date, there have been no studies of genome-wide DNA methylation profiling of NETs. This study sets out to determine the DNA methylation profiles of low, intermediate and high grade pancreatic NET liver metastases with the intention of identifying dysregulated biological pathways in the development of these tumors. A protocol for the analysis formalin-fixed paraffin embedded tissue (FFPE) has also been developed in order to study these tumors in significant numbers following this pilot study.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr Christina Thirlwell
#1556 Staging in Small Bowel Neuroendocrine Tumours: Roles and Shortcomings
Introduction: Small bowel neuroendocrine tumours (SB NETs) frequently present with lymph node and/or distant metastases
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Ashley Clift
#1712 Epidemiological Factors at Diagnosis in a Large Cohort of Patients with Pancreatic Neuroendocrine Tumours
Introduction: Pancreatic neuroendocrine tumours(pNETs) are among the most frequent NETs with an increasing incidence.However,recent epidemiological data reports are limited.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Dr Apostolos Koffas